ABOUT US

Oculis is a clinical stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases for both back- and front-of-the-eye in order to improve the sight and the lives of patients worldwide.

INNOVATIVE TOPICAL THERAPIES FOR MILLIONS OF PATIENTS WORLDWIDE

The Oculis strategy is to build an innovative ophthalmology company unlike any other. Our plan is to:

    • Further advance our lead candidates: OCS-01 as a new therapeutic option for DME and post-cataract inflammation and OCS-02 for front-of-the-eye inflammation.
    • Leverage our formulation discovery platforms (OPTIREACH technology and others) to develop a clinical pipeline of topical treatments for back and forth-of-the-eye diseases.

TAKING TREATMENT FROM INJECTIONS TO DROPS FOR RETINAL DISEASES

Our novel OPTIREACH formulation technology provides an unprecedented technical advancement in ocular drug delivery, particularly for back-of-the-eye diseases that are currently managed by invasive methods such as intraocular injections or implants

OCS-01 A POTENTIAL ONCE DAILY TREATMENT FOR POST-CATARACT SURGERY INFLAMMATION

OCS-01, our most advanced product candidate based on OPTIREACH technology, has recently completed two Phase 2 studies, one in DME and one in Pain and Inflammation following cataract surgery. The study in DME is the first proof-of-concept of a topical drug effect on retinal edema and is also a successful proof-of-concept for the OPTIREACH formulation technology. If approved in DME, it has the potential to provide a new option for patients whose current therapies are limited to intravitreal injections or implants. The study in post-cataract surgery is the first proof-of-concept of a once daily topical steroid for treating Inflammation and Pain following ocular surgery. OCS-01 is moving into phase III, following a positive End of Phase 2 meeting, in both indications.